Cargando…
Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice
BACKGROUND: There is an urgent need to develop and test novel compounds against malaria infection. Carrageenans, sulphated polysaccharides derived from seaweeds, have been previously shown to inhibit Plasmodium falciparum in vitro. However, they are inflammatory and alter the permeability of the blo...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295290/ https://www.ncbi.nlm.nih.gov/pubmed/25495520 http://dx.doi.org/10.1186/1475-2875-13-487 |
_version_ | 1782352818457280512 |
---|---|
author | Recuenco, Frances C Takano, Ryo Chiba, Shiori Sugi, Tatsuki Takemae, Hitoshi Murakoshi, Fumi Ishiwa, Akiko Inomata, Atsuko Horimoto, Taisuke Kobayashi, Yoshiyasu Horiuchi, Noriyuki Kato, Kentaro |
author_facet | Recuenco, Frances C Takano, Ryo Chiba, Shiori Sugi, Tatsuki Takemae, Hitoshi Murakoshi, Fumi Ishiwa, Akiko Inomata, Atsuko Horimoto, Taisuke Kobayashi, Yoshiyasu Horiuchi, Noriyuki Kato, Kentaro |
author_sort | Recuenco, Frances C |
collection | PubMed |
description | BACKGROUND: There is an urgent need to develop and test novel compounds against malaria infection. Carrageenans, sulphated polysaccharides derived from seaweeds, have been previously shown to inhibit Plasmodium falciparum in vitro. However, they are inflammatory and alter the permeability of the blood–brain barrier, raising concerns that their use as a treatment for malaria could lead to cerebral malaria (CM), a severe complication of the disease. In this work, the authors look into the effects of the administration of λ-carrageenan to the development and severity of CM in BALB/c mice, a relatively non-susceptible model, during infection with the ANKA strain of Plasmodium berghei. METHODS: Five-week-old female BALB/c mice were infected with P. berghei intraperitoneally. One group was treated with λ-carrageenan (PbCGN) following the 4-day suppressive test protocol, whereas the other group was not treated (PbN). Another group of healthy BALB/c mice was similarly given λ-carrageenan (CGN) for comparison. The following parameters were assessed: parasitaemia, clinical signs of CM, and mortality. Brain and other vital organs were collected and examined for gross and histopathological lesions. Evans blue dye assays were employed to assess blood–brain barrier integrity. RESULTS: Plasmodium berghei ANKA-infected BALB/c mice treated with λ-carrageenan died earlier than those that received no treatment. Histopathological examination revealed that intracerebral haemorrhages related to CM were present in both groups of infected BALB/c mice, but were more numerous in those treated with λ-carrageenan than in mock-treated animals. Inflammatory lesions were also observed only in the λ-carrageenan-treated mice. These observations are consistent with the clinical signs associated with CM, such as head tilt, convulsions, and coma, which were observed only in this group, and may account for the earlier death of the mice. CONCLUSION: The results of this study indicate that the administration of λ-carrageenan exacerbates the severe brain lesions and clinical signs associated with CM in BALB/c mice infected with P. berghei ANKA. |
format | Online Article Text |
id | pubmed-4295290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42952902015-01-16 Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice Recuenco, Frances C Takano, Ryo Chiba, Shiori Sugi, Tatsuki Takemae, Hitoshi Murakoshi, Fumi Ishiwa, Akiko Inomata, Atsuko Horimoto, Taisuke Kobayashi, Yoshiyasu Horiuchi, Noriyuki Kato, Kentaro Malar J Research BACKGROUND: There is an urgent need to develop and test novel compounds against malaria infection. Carrageenans, sulphated polysaccharides derived from seaweeds, have been previously shown to inhibit Plasmodium falciparum in vitro. However, they are inflammatory and alter the permeability of the blood–brain barrier, raising concerns that their use as a treatment for malaria could lead to cerebral malaria (CM), a severe complication of the disease. In this work, the authors look into the effects of the administration of λ-carrageenan to the development and severity of CM in BALB/c mice, a relatively non-susceptible model, during infection with the ANKA strain of Plasmodium berghei. METHODS: Five-week-old female BALB/c mice were infected with P. berghei intraperitoneally. One group was treated with λ-carrageenan (PbCGN) following the 4-day suppressive test protocol, whereas the other group was not treated (PbN). Another group of healthy BALB/c mice was similarly given λ-carrageenan (CGN) for comparison. The following parameters were assessed: parasitaemia, clinical signs of CM, and mortality. Brain and other vital organs were collected and examined for gross and histopathological lesions. Evans blue dye assays were employed to assess blood–brain barrier integrity. RESULTS: Plasmodium berghei ANKA-infected BALB/c mice treated with λ-carrageenan died earlier than those that received no treatment. Histopathological examination revealed that intracerebral haemorrhages related to CM were present in both groups of infected BALB/c mice, but were more numerous in those treated with λ-carrageenan than in mock-treated animals. Inflammatory lesions were also observed only in the λ-carrageenan-treated mice. These observations are consistent with the clinical signs associated with CM, such as head tilt, convulsions, and coma, which were observed only in this group, and may account for the earlier death of the mice. CONCLUSION: The results of this study indicate that the administration of λ-carrageenan exacerbates the severe brain lesions and clinical signs associated with CM in BALB/c mice infected with P. berghei ANKA. BioMed Central 2014-12-11 /pmc/articles/PMC4295290/ /pubmed/25495520 http://dx.doi.org/10.1186/1475-2875-13-487 Text en © Recuenco et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Recuenco, Frances C Takano, Ryo Chiba, Shiori Sugi, Tatsuki Takemae, Hitoshi Murakoshi, Fumi Ishiwa, Akiko Inomata, Atsuko Horimoto, Taisuke Kobayashi, Yoshiyasu Horiuchi, Noriyuki Kato, Kentaro Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice |
title | Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice |
title_full | Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice |
title_fullStr | Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice |
title_full_unstemmed | Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice |
title_short | Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice |
title_sort | lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by plasmodium berghei anka in balb/c mice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295290/ https://www.ncbi.nlm.nih.gov/pubmed/25495520 http://dx.doi.org/10.1186/1475-2875-13-487 |
work_keys_str_mv | AT recuencofrancesc lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT takanoryo lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT chibashiori lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT sugitatsuki lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT takemaehitoshi lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT murakoshifumi lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT ishiwaakiko lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT inomataatsuko lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT horimototaisuke lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT kobayashiyoshiyasu lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT horiuchinoriyuki lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice AT katokentaro lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice |